National Coordinating and Evaluation Center
Sickle Cell Disease Association of the Piedmont (Greensboro, NC) Print

Sickle Cell Disease Association
of the Piedmont

Project Title: Newborn Case Management and Follow-up Project
Principal Investigator: Gladys A. Robinson, M.Ed.
Organization: Sickle Cell Disease Association of the Piedmont
Address: P. O. Box 20964, Greensboro, NC 27420
Street Address: 1102 East Market Street
Contact Person: Gladys A. Robinson
Phone: 336.274.1507 Fax: 336.274.4251
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Web Site: http://www.scdap.org/

Purpose

The Sickle Cell Disease Association of the Piedmont proposes a continuation of its Newborn Case Management and Follow-up Project to:

  1. demonstrate a successful model of comprehensive case management, home teaching and follow-up of 115 (one hundred-fifteen) newborns and children (ages 0-5) with sickle cell disease (SCD) in 6 counties of North Carolina;
  2. provide face to face genetic counseling of parents of 200 (two-hundred) newborns with hemoglobinopathy trait;
  3. demonstrate the success of SCDAP in partnering with the NC Newborn Screening Program, three comprehensive sickle cell centers, and primary providers in the comprehensive care for infants with SCD; and
  4. collaborate with the National Coordinating and Evaluation Center to support data collection and standardization of community-based models.

Challenges

In FY 2002/03, 900 new Southeast Asians resettled in Guilford County, and 52,000 Hispanics now live in the 6 county area. No information is yet available on the incidence of hgb S, however, we noted a significant increase of abnormal hgb in newborns among these ethnic groups. Barriers to serving parents of infants/children of diverse ethnic backgrounds are language and culture. Parents of the pediatric clients (current) speak 13 different languages. We propose hiring interpreters to bridge communications. Based on a study by Telfair, Robinson, et.al. (1999), the parents/guardians of SCDAP’s infant/child clientele were mostly single heads of households and underemployed. These parents face barriers of having low wage jobs, lack of transportation and a lower quality of health care.

Two earlier challenges that have since been resolved were:

  1. poor attitudes of hospital staff and slow response of emergency rooms (addressed through the initiation of a Pediatric Task Force at Moses Cone Health Systems); and
  2. the State Laboratory’s procedure to mail letters to parents explaining the child’s hgb. trait, thus, parents often fail to seek counseling. This practice has been suspended (in SCDAP’s area) to promote aggressive outreach and counseling.

Goals and Objectives

  1. Identify an estimated 25 newborns with SCD in the six counties through notification, confirmation testing and counseling parents;
  2. Reduce morbidity and mortality of 50 infants (25 newborns plus an additional 25 infants/children with SCD, ages 0+ to 12 months, from prior grant period) through comprehensive case management, which includes assessment of needs, development of a care coordination plan, referral to primary providers and comprehensive centers, and other resources, and increasing parents’ knowledge/management skills through home teaching sessions;
  3. Promote healthy growth and development of 65 children with SCD (ages 1-5 years) within the home/family; addressing physical/ emotional readiness and transitioning to pre-school;
  4. Conduct face to face genetic counseling, education and testing to 200 parents of newborns with trait, to assist parents in decision making and understanding of inheritance patterns;
  5. Educate area primary care professionals about disease management strategies to improve care for persons with SCD; about recent findings in SCD management and therapies;
  6. Share data collected and findings through quarterly and annual reports submitted to the State Program and NCEC.

Methodology

Nurse/Case Managers will conduct:

  1. Identification, retesting and follow-up of newborns/infants, provide counseling to parents within the first month of life and complete detail assessment forms on 25 newborns;
  2. Provide Case management for 50 newborns/infants (25 newborns plus an additional 25 newborns from prior grant period, ages 0 to 12 mos.); develop a care plan with appropriate referrals to primary care providers, comprehensive centers and other agencies; Conduct follow-up visits and 5 home teaching sessions;
  3. Promote continuous growth and development for 65 infants/children, ages 1-5, through bi-monthly Support Group Meetings and continuing education of parents. Educator/counselor will conduct:
  4. Genetic counseling with 6 months follow-up to parents of newborns with sickle cell trait; and
  5. Educator and Project Director will conduct 1 major workshop for providers on SCD treatment and management, implement in-service trainings at an area hospital, and mail treatment updates to providers.

Evaluation

Data will be collected and analyzed over the 2-year period on newborn/infant/children and families. The Parent/Child Pre and Post Knowledge Questionnaires will be given prior to and at the end of teachings to achieve a score of 85%. Home teaching tests and feedback will assess parents’ knowledge and competence. Nursing notes will indicate compliance with recommended treatment regimen. Genetic counseling of 200 parents of newborns with trait will be assessed by using pre and post knowledge tests (to attain score of 85%), with follow-up tests six months later (w/ 75% retention).

Experience to Date

  1. SCDAP was awarded a MCH grant in 2002/03 for newborn screening; its CEO presented on the project’s database development and agency collaborations at the NCEC meeting.
  2. This proposal is supported by data collected in a previous project “Pediatric Home Teaching for Parents of Children with SCD”, (Telfair, SCDAP, 1994), funded by Duke Endowment.
  3. SCDAP sub-contracted with Duke University Comprehensive Sickle Cell Center- funded by the NHLBI (1987-96).
  4. SCDAP received the 1996 Archon Award from Sigma Theta Tau International Honor Society of Nursing for a Collaborative Interdisciplinary Program Model resulting in improved health care delivery.
  5. The project director, Marietta Douglas peer reviewed “Guidelines for Management of Acute and Chronic Pain in Sickle Cell Disease”, American Pain Society in 1999. SCDAP is a model that can be duplicated by other community-based agencies in the collaboration and appropriate linkage of parents, local health providers, comprehensive centers and state programs in providing quality care for infants with sickle cell disease.

Text of Annotation

SCDAP proposes a Newborn Case Management and Follow-up Model to demonstrate that community –based sickle cell centers can provide effective case management, medical/health care coordination, and follow-up of newborns/infants with SCD identified through state newborn screening programs. SCDAP uses its home teaching program to educate and improve the skills of parents in caring for their infant. The project also demonstrates that CBOs are excellent avenues for providing outreach and genetic counseling of parents of newborns with hemoglobinopathy variants to assist with informed decision-making.

 

Welcome to the website of the National Coordinating and Evaluation Center- SCDAA for the Sickle Cell Disease Newborn Screening Program. Please take a moment to read the following statement regarding policy, confidentiality, and disclaimers. Once you click your acceptance below, you will be free to navigate throughout the site. Thank you for your cooperation, and enjoy your visit!

TERMS AND CONDITIONS OF USE OF SICKLECELLDISEASE.NET

AGREEMENT

BY ENTERING THE NCEC-SCDAA SITE, YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE READ AND UNDERSTAND THESE TERMS AND CONDITIONS OF USE OF SICKLECELLDISEASE.NET, THAT THE PROVISIONS, DISCLOSURES AND DISCLAIMERS SET FORTH BELOW ARE FAIR AND REASONABLE, AND THAT YOUR AGREEMENT TO FOLLOW AND BE BOUND BY THEM IS VOLUNTARY AND IS NOT THE RESULT OF FRAUD, DURESS OR UNDUE INFLUENCE EXERCISED UPON YOU BY ANY PERSON OR ENTITY. YOU ALSO AGREE TO HOLD NCEC AND ITS GRANTEES, AND EACH OF THEIR OFFICERS, DIRECTORS, MEMBERS, AND AGENTS HARMLESS FROM ANY CLAIM, COMPLAINT OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH YOUR USE OF THE SITE.

SUMMARY OF IMPORTANT LEGAL INFORMATION

The sicklecelldisease.net website (the "Site") is produced for the National Coordinating and Evaluation Center (NCEC) -SCDAA, the grantees participating in the Sickle Cell Disease Newborn Screening Program and their partners. All use of the Site is subject to the Terms and Conditions set forth below. By entering and using the Site, you acknowledge that you have read and understood such Terms and Conditions and that you agree to abide by them. The Site is designed for informational and educational purposes only. NCEC does not endorse, guarantee, warrant, or recommend any products or services discussed or advertised on the Site or linked from the Site. The NCEC-SCDAA retains all copyrights and other proprietary rights in or relating to any content, including any software or educational materials, provided on the Site. You may download and print a small number of copies of the content for scientific or educational uses. You may not sell, transfer, reproduce, transmit, distribute, perform or display such content for any commercial purpose without the express consent of the NCEC-SCDAA.

PRIVACY POLICY NCEC-SCDAA provides the following privacy policy (the "Privacy Policy") in order to demonstrate our firm commitment to privacy. The Privacy Policy may be amended from time to time. The NCEC home page will indicate the date that the Privacy Policy was most recently updated.

a. Collection of Personal Information. NCEC -SCDAA may ask for information about our users at the point of downloading educational materials. This information tells us about the types of people (e.g., providers vs. patients, grantees vs. nongrantees) who use the Site and helps us in the development of materials for our grantees and their clients.

b. Use of Personally Identifiable Information. NCEC-SCDAA will not sell or otherwise transfer or disclose personally identifiable information to third parties without the user's prior consent except as may be required by federal, state or local law, or by exigent circumstances. NCEC-SCDAA also may use your profile information on an aggregate basis -- without personal identifiers -- to develop and display new features and content for the Site, and to provide others with aggregate information about our users and the usage patterns of the Site. NCEC-SCDAA also may perform statistical analyses of user behavior (on a de-identified aggregate basis) in order to measure interest in and use of the various areas of the Site.

c. Retention of User Information. It is not possible for a user to delete his or her profile from our database, nor is it feasible to delete all traces of a user's activity in the system. Messages posted to a forum are examples of user activities that are not feasible to delete.

d. Voluntary Disclosure of Personally Identifiable Information on Forum Boards. Users should be aware that when they voluntarily disclose personally identifiable information (for example user name, email address) on an Interactive Area of the Site, that information, along with any substantive information disclosed in the user's communication, can be collected and correlated and used by third parties and may result in unsolicited messages from third parties. Such activities are beyond the control of the NCEC and the NCEC is not responsible for the discoverability of any user's identify by methods beyond our control.

e. Cookie Technology. NCEC collects non-personal identification information through the use of "cookie" technology and/or Internet Protocol ("IP") address tracking. Cookies are small text files a website can use to recognize repeat users and facilitate the user's ongoing access to and use of the site. Non-personal identification information might include the browser used by the user, the type of computer, the operating systems, the Internet service providers and other similar information. The NCEC system also automatically gathers information about the areas the user visits on the Site and about the links the user may select from within the Site to other sites. NCEC cannot control the use of cookies by advertisers or third parties displaying data on the Site or whose sites a user visits or links to from the Site. Most browsers are set to accept cookies. You can set yours to refuse cookies, or to alert you when cookies are being sent.

f. Links to other sites. The Site contains links to third party websites. These links are provided solely as a convenience to users and not as a guarantee, warranty, or recommendation by NCEC of the content on such third-party websites or as an indication of any affiliation, sponsorship or endorsement of such third party websites. NCEC is not responsible for the content of linked third-party sites and does not make any representations regarding the privacy practices of, or the content or accuracy of materials on, such third-party websites. If you decide to access linked third-party websites, you do so at your own risk. Your use of third-party websites is subject to the terms of use for such sites.

g. Security of Information. NCEC is committed to keeping user information secure, and uses industry standard technology in an attempt to achieve that goal.

h. Parental Permission. NCEC does not intend that children will use the Site. Some of the information available on the Site may not be appropriate for children. USERS UNDER 18 YEARS OF AGE MUST OBTAIN PARENTAL PERMISSION TO USE THE SITE. Adults should not assist unauthorized children to access the Site. NCEC will not knowingly collect, use or disclose personally identifiable information about visitors under 18 years of age.

     

For security reasons,
you must accept the Term and Conditions of SICKLECELLDISEASE.NET
in order to be able to navigate throughout the site.
Thank you.
Disclaimer
Home